Kainos Medicine, Inc. (KOSDAQ:284620)

Market Cap	35.56B
Revenue (ttm)	820.31M
Net Income (ttm)	-10.72B
Shares Out	32.71M
EPS (ttm)	-367.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	883,908
Average Volume	481,084
Open	1,200.00
Previous Close	1,192.00
Day's Range	1,069.00 - 1,245.00
52-Week Range	960.00 - 6,000.00
Beta	1.28
RSI	50.94
Earnings Date	Nov 14, 2025

About Kainos Medicine

Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 284620

Financial Performance

In 2024, Kainos Medicine's revenue was 590.37 million, an increase of 120.85% compared to the previous year's 267.31 million. Losses were -12.19 billion, -19.99% less than in 2023.